A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Trial Profile

A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Elosulfase alfa (Primary)
  • Indications Mucopolysaccharidosis IV
  • Focus Adverse reactions
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 19 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 11 Sep 2014 The Endpoint assessment duration has been changed from 52 weeks to 208 weeks, according to ClinicalTrials.gov.
    • 11 Sep 2014 The dosage duration has been changed from 52 weeks to 208 weeks according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top